<![CDATA[Genmab — November 2015]]>Dara subcutan kan være vores løsning, hvis der er et problem der.

]]>https://dev.proinvestor.com/forum/topic/451488/genmab-november-2015RSS for NodeThu, 18 Jun 2026 11:52:37 GMTSun, 01 Nov 2015 06:22:09 GMT60<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 19:27:05 GMT]]>har modtaget den via
mail

]]>https://dev.proinvestor.com/forum/post/10107370https://dev.proinvestor.com/forum/post/10107370Mon, 30 Nov 2015 19:27:05 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 19:14:11 GMT]]>Er det noget man kan tilgå Budweis? 🙂

]]>https://dev.proinvestor.com/forum/post/10107367https://dev.proinvestor.com/forum/post/10107367Mon, 30 Nov 2015 19:14:11 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:25:32 GMT]]>genmab analysen er på tre sider

]]>https://dev.proinvestor.com/forum/post/10107364https://dev.proinvestor.com/forum/post/10107364Mon, 30 Nov 2015 18:25:32 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:24:46 GMT]]>nope

]]>https://dev.proinvestor.com/forum/post/10107368https://dev.proinvestor.com/forum/post/10107368Mon, 30 Nov 2015 18:24:46 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:22:35 GMT]]>Dissekerer de pipelinen op i kurspoint ? Det kunne være interessant at høre, hvor meget de enkelte produkter er normeret til ?

]]>https://dev.proinvestor.com/forum/post/10107366https://dev.proinvestor.com/forum/post/10107366Mon, 30 Nov 2015 18:22:35 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:20:20 GMT]]>nemlig - det er en solid rapport

]]>https://dev.proinvestor.com/forum/post/10107363https://dev.proinvestor.com/forum/post/10107363Mon, 30 Nov 2015 18:20:20 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:19:51 GMT]]>Over 100 sider fra Deutsche !

]]>https://dev.proinvestor.com/forum/post/10107362https://dev.proinvestor.com/forum/post/10107362Mon, 30 Nov 2015 18:19:51 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:19:00 GMT]]>Tak Budweis. 🙂

]]>https://dev.proinvestor.com/forum/post/10107369https://dev.proinvestor.com/forum/post/10107369Mon, 30 Nov 2015 18:19:00 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:17:12 GMT]]>🙂 Let it come

]]>https://dev.proinvestor.com/forum/post/10107365https://dev.proinvestor.com/forum/post/10107365Mon, 30 Nov 2015 18:17:12 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:16:15 GMT]]>Fra dagens Deutche analyse af pharma og biotek sektoren i EU - "In our view Actelion, Genmab and SOBI are the most likely takeout targets as they have strong recently approved potential blockbuster products and better shareholder structure"

]]>https://dev.proinvestor.com/forum/post/10107371https://dev.proinvestor.com/forum/post/10107371Mon, 30 Nov 2015 18:16:15 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:13:07 GMT]]>Kommer der nyt fra både Castor og Pollux ?

]]>https://dev.proinvestor.com/forum/post/10107358https://dev.proinvestor.com/forum/post/10107358Mon, 30 Nov 2015 18:13:07 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:10:06 GMT]]>Jamen Gen503 er jo det
der kommer på ASH nu

]]>https://dev.proinvestor.com/forum/post/10107361https://dev.proinvestor.com/forum/post/10107361Mon, 30 Nov 2015 18:10:06 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:08:49 GMT]]>Gen503 var jo et fase 1/2 dose escalation study, dar var baggrunden for Pollux.

]]>https://dev.proinvestor.com/forum/post/10107359https://dev.proinvestor.com/forum/post/10107359Mon, 30 Nov 2015 18:08:49 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:04:53 GMT]]>Har nu mere ondt af Marshall Wace 😉

]]>https://dev.proinvestor.com/forum/post/10107355https://dev.proinvestor.com/forum/post/10107355Mon, 30 Nov 2015 18:04:53 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 18:04:28 GMT]]>Hvorfor er der to dara/len(rev)
/dex studier - Gen503 og Pollux?

]]>https://dev.proinvestor.com/forum/post/10107354https://dev.proinvestor.com/forum/post/10107354Mon, 30 Nov 2015 18:04:28 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 17:29:05 GMT]]>se udnyttelsesgraden og sige et eller andet begavet om det?

]]>https://dev.proinvestor.com/forum/post/10107353https://dev.proinvestor.com/forum/post/10107353Mon, 30 Nov 2015 17:29:05 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 17:28:20 GMT]]>http://oasm.finanstilsynet.dk/dk/vismeddelelse.aspx?aid=5fb5cd59-0024-471a-b561-b3eff2b89715 31 aug. 59.322.130 stk - nu 209.133 stk's flere aktier. Nogen der kan

]]>https://dev.proinvestor.com/forum/post/10107356https://dev.proinvestor.com/forum/post/10107356Mon, 30 Nov 2015 17:28:20 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 16:53:37 GMT]]>
Access to this page has been denied

px-captcha

favicon

(seekingalpha.com)

]]>https://dev.proinvestor.com/forum/post/10107357https://dev.proinvestor.com/forum/post/10107357Mon, 30 Nov 2015 16:53:37 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 16:53:28 GMT]]>PFS 19.4 mdr med Elo-Len-Dex (14.9 mdr med Len-Dex alene) - det er den PFS Dara-Len-Dex gerne skal slå i Pollux studiet. Kan vi få en indikation af PFS fra Dara-Len-Dex fase 2 kombi studiet på ASH?

]]>https://dev.proinvestor.com/forum/post/10107360https://dev.proinvestor.com/forum/post/10107360Mon, 30 Nov 2015 16:53:28 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 15:09:05 GMT]]>Så kom emplicit godkendelsen.

]]>https://dev.proinvestor.com/forum/post/10107348https://dev.proinvestor.com/forum/post/10107348Mon, 30 Nov 2015 15:09:05 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 15:08:49 GMT]]>
Link Preview Image
FDA approves new Bristol-Myers treatment for multiple myeloma

The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone. The National Cancer Institute estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States in 2015.

favicon

Yahoo Finance (finance.yahoo.com)

]]>https://dev.proinvestor.com/forum/post/10107347https://dev.proinvestor.com/forum/post/10107347Mon, 30 Nov 2015 15:08:49 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 13:55:13 GMT]]>Tror det gik på den immunmodulerende effekt - glæder mig til det hele, men kursmæssigt er det måske vigtigst med de korte briller at Dara-Rev-Dex kombien viser overbevisende CR

]]>https://dev.proinvestor.com/forum/post/10107346https://dev.proinvestor.com/forum/post/10107346Mon, 30 Nov 2015 13:55:13 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 13:51:22 GMT]]>Håber guldkornet er så stort at de må se sig nødsaget til at melde ud fredag:-) sagde JDW ikke noget med at ørerne ville gøre ondt med alle de gode nyheder?

]]>https://dev.proinvestor.com/forum/post/10107345https://dev.proinvestor.com/forum/post/10107345Mon, 30 Nov 2015 13:51:22 GMT<![CDATA[Reply to Genmab — November 2015 on Mon, 30 Nov 2015 13:43:51 GMT]]>Der kommer meddelser fra Genmab - om de kommer løbende eller før åbning mandag morgen er svært at sige.

]]>https://dev.proinvestor.com/forum/post/10107351https://dev.proinvestor.com/forum/post/10107351Mon, 30 Nov 2015 13:43:51 GMT